The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

Treatment options for metastatic renal cell carcinoma (RCC) have been expanding in the last years, from the consolidation of several anti-angiogenic agents to the approval of immune checkpoint inhibitors (ICIs). The rationale for the use of immunomodulating agents derived from the observation that R...

Descripción completa

Detalles Bibliográficos
Autores principales: Brighi, Nicole, Farolfi, Alberto, Conteduca, Vincenza, Gurioli, Giorgia, Gargiulo, Stefania, Gallà, Valentina, Schepisi, Giuseppe, Lolli, Cristian, Casadei, Chiara, De Giorgi, Ugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966461/
https://www.ncbi.nlm.nih.gov/pubmed/31817109
http://dx.doi.org/10.3390/cancers11121935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966461/
https://www.ncbi.nlm.nih.gov/pubmed/31817109
http://dx.doi.org/10.3390/cancers11121935

Ejemplares similares